Acute Cardiovascular Care Unit, Cardiology, Hospital Germans Trias i Pujol, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris Cedex 13, France.
ESC Heart Fail. 2023 Feb;10(1):568-577. doi: 10.1002/ehf2.14132. Epub 2022 Nov 11.
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is currently one of the most used devices in refractory cardiogenic shock. However, there is a lack of evidence on how to set the 'optimal' flow. We aimed to describe the evolution of VA-ECMO flows in a cardiogenic shock population and determine the risk factors of 'high-ECMO flow'.
A 7 year database of patients supported with VA-ECMO was used. Based on the median flow during the first 48 h of the VA-ECMO run, patients were classified as 'high-flow' or 'low-flow', respectively, when median ECMO flow was ≥3.6 or <3.6 L/min. Outcomes included rates of ventilator-associated pneumonia, ECMO-related complications, days on ECMO, days on mechanical ventilation, intensive care unit and hospitalization lengths of stay, and in-hospital and 60 day mortality. Risk factors of high-ECMO flow were assessed using univariate and multivariate cox regression. The study population included 209 patients on VA-ECMO, median age was 51 (40-59) years, and 78% were males. The most frequent aetiology leading to cardiogenic shock was end-stage dilated cardiomyopathy (57%), followed by acute myocardial infarction (23%) and fulminant myocarditis (17%). Among the 209 patients, 105 (50%) were classified as 'high-flow'. This group had a higher rate of ischaemic aetiology (16% vs. 30%, P = 0.023) and was sicker at admission, in terms of worse Simplified Acute Physiology Score II score [40 (26-58) vs. 56 (42-74), P < 0.001], higher lactate [3.6 (2.2-5.8) mmol/L vs. 5.2 (3-9.7) mmol/L, P < 0.001], and higher aspartate aminotransferase [97 (41-375) U/L vs. 309 (85-939) U/L, P < 0.001], among others. The 'low-flow' group had less ventilator-associated pneumonia (40% vs. 59%, P = 0.007) and less days on mechanical ventilation [4 (1.5-7.5) vs. 6 (3-12) days, P = 0.009]. No differences were found in lengths of stay or survival according to the ECMO flow. The multivariate analysis showed that risk factors independently associated with 'high-flow' were mechanical ventilation at cannulation [odds ratio (OR) 3.9, 95% confidence interval (CI) 2.1-7.1] and pre-ECMO lactate (OR 1.1, 95% CI 1.0-1.2).
In patients with refractory cardiogenic shock supported with VA-ECMO, sicker patients had higher support since early phases, presenting thereafter higher rates of ventilator-associated pneumonia but similar survival compared with patients with lower flows.
体外膜肺氧合(VA-ECMO)目前是治疗难治性心源性休克最常用的设备之一。然而,关于如何设定“最佳”流量缺乏证据。我们旨在描述心源性休克患者中 VA-ECMO 流量的演变,并确定“高 ECMO 流量”的危险因素。
使用了一个为期 7 年的接受 VA-ECMO 支持的患者数据库。根据 VA-ECMO 运行前 48 小时的中位数流量,当 ECMO 流量中位数≥3.6 或 <3.6 L/min 时,患者分别被归类为“高流量”或“低流量”。结果包括呼吸机相关性肺炎、ECMO 相关并发症、ECMO 天数、机械通气天数、重症监护病房和住院时间、住院和 60 天死亡率。使用单因素和多因素 Cox 回归评估高 ECMO 流量的危险因素。研究人群包括 209 名接受 VA-ECMO 的患者,中位年龄为 51(40-59)岁,78%为男性。导致心源性休克的最常见病因是终末期扩张型心肌病(57%),其次是急性心肌梗死(23%)和暴发性心肌炎(17%)。在 209 名患者中,105 名(50%)被归类为“高流量”。该组的缺血性病因发生率更高(16% vs. 30%,P=0.023),入院时病情更严重,简化急性生理学评分 II 评分更高[40(26-58) vs. 56(42-74),P<0.001],乳酸水平更高[3.6(2.2-5.8)mmol/L vs. 5.2(3-9.7)mmol/L,P<0.001],天冬氨酸转氨酶水平更高[97(41-375)U/L vs. 309(85-939)U/L,P<0.001],等等。“低流量”组呼吸机相关性肺炎发生率较低(40% vs. 59%,P=0.007),机械通气天数较短[4(1.5-7.5) vs. 6(3-12)天,P=0.009]。根据 ECMO 流量,住院时间或生存率没有差异。多因素分析显示,与“高流量”相关的独立危险因素是插管时机械通气[比值比(OR)3.9,95%置信区间(CI)2.1-7.1]和 ECMO 前乳酸(OR 1.1,95% CI 1.0-1.2)。
在接受 VA-ECMO 支持的难治性心源性休克患者中,病情较重的患者在早期阶段获得了更高的支持,此后呼吸机相关性肺炎发生率较高,但与低流量患者的生存率相似。